Effect of methylene diphosphate combined with strontium chloride in the treatment of bone pain caused by multiple bone metastases

中国基层医药 Pub Date : 2020-04-01 DOI:10.3760/CMA.J.ISSN.1008-6706.2020.07.020

Jianguo Liu, Xiaoli Liu, Jinjun Kang, Xu Zhang

{"title":"Effect of methylene diphosphate combined with strontium chloride in the treatment of bone pain caused by multiple bone metastases","authors":"Jianguo Liu, Xiaoli Liu, Jinjun Kang, Xu Zhang","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.07.020","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the clinical efficacy of Yunke(99TC-MDP) combined with strontium 89SrCl2 in the treatment of bone pain in patients with multiple bone metastases. \n \n \nMethods \nThe clinical data of 95 patients with multiple bone metastases admitted to the General Hospital of Datong Coal Group from August 2014 to July 2019 were retrospectively analyzed.According to the different treatment methods, they were divided into three groups: 37 patients in Yunke group were treated with Yunke alone, 29 patients in 89SrCl2 group were treated with 89SrCl2 alone, 29 patients in combination group were treated with Yunke combined with 89SrCl2.All patients were treated for 5 days, with a course of treatment per month.The clinical efficacy, analgesic time and adverse reactions of the three groups were compared. \n \n \nResults \nAfter treatment, the pain relief rates of the Yunke group, the 89SrCl2 group and the combination group were 67.6%(25/37), 69.0%(20/29) and 79.3%(23/29), respectively.The pain relief rate of the combined group was higher than that of the Yunke group(χ2=4.25, P<0.05). The effective rate of bone metastases in the combined group was 41.4%(12/29), which was higher than that in the Yunke group[0.0%(0/37)], the 89SrCl2 group[17.2%(5/29)], the differences were statistically significant(χ2=13.09, 10.54, all P<0.01). No serious adverse reactions were found in the three groups. \n \n \nConclusion \nYunke combined with 89SrCl2 is superior to 89SrCl2 alone, and it is safe in the treatment of bone metastases. \n \n \nKey words: \nNeoplasm metastasis; Metastatic carcinoma of bone; Bone pain; Methylene diphosphate; Strontium chloride; Comparative study","PeriodicalId":10226,"journal":{"name":"中国基层医药","volume":"27 1","pages":"855-858"},"PeriodicalIF":0.0000,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国基层医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.07.020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To investigate the clinical efficacy of Yunke(99TC-MDP) combined with strontium 89SrCl2 in the treatment of bone pain in patients with multiple bone metastases. Methods The clinical data of 95 patients with multiple bone metastases admitted to the General Hospital of Datong Coal Group from August 2014 to July 2019 were retrospectively analyzed.According to the different treatment methods, they were divided into three groups: 37 patients in Yunke group were treated with Yunke alone, 29 patients in 89SrCl2 group were treated with 89SrCl2 alone, 29 patients in combination group were treated with Yunke combined with 89SrCl2.All patients were treated for 5 days, with a course of treatment per month.The clinical efficacy, analgesic time and adverse reactions of the three groups were compared. Results After treatment, the pain relief rates of the Yunke group, the 89SrCl2 group and the combination group were 67.6%(25/37), 69.0%(20/29) and 79.3%(23/29), respectively.The pain relief rate of the combined group was higher than that of the Yunke group(χ2=4.25, P<0.05). The effective rate of bone metastases in the combined group was 41.4%(12/29), which was higher than that in the Yunke group[0.0%(0/37)], the 89SrCl2 group[17.2%(5/29)], the differences were statistically significant(χ2=13.09, 10.54, all P<0.01). No serious adverse reactions were found in the three groups. Conclusion Yunke combined with 89SrCl2 is superior to 89SrCl2 alone, and it is safe in the treatment of bone metastases. Key words: Neoplasm metastasis; Metastatic carcinoma of bone; Bone pain; Methylene diphosphate; Strontium chloride; Comparative study

查看原文本刊更多论文

二磷酸亚甲基联合氯化锶治疗多发性骨转移所致骨痛的疗效观察

目的探讨云科(99TC-MDP)联合89SrCl2锶治疗多发性骨转移患者骨痛的临床疗效。方法回顾性分析2014年8月至2019年7月大同煤炭集团总医院收治的95例多发性骨转移患者的临床资料。根据治疗方法的不同，将其分为三组:云科组37例患者单独应用云科治疗，89SrCl2组29例患者单独应用89SrCl2治疗，云科联合89SrCl2组29例患者联合应用云科治疗。所有患者治疗5天，每月1个疗程。比较三组患者的临床疗效、镇痛时间及不良反应。结果治疗后，云科组、89SrCl2组和联合组的疼痛缓解率分别为67.6%(25/37)、69.0%(20/29)和79.3%(23/29)。联合组疼痛缓解率高于云科组(χ2=4.25, P<0.05)。联合组骨转移有效率为41.4%(12/29)，高于云科组[0.0%(0/37)]、89SrCl2组[17.2%(5/29)]，差异均有统计学意义(χ2=13.09、10.54，均P<0.01)。三组患者均未见严重不良反应。结论云科联合89SrCl2治疗骨转移瘤的疗效优于单用89SrCl2，安全可靠。关键词:肿瘤转移;骨转移癌;骨痛;亚甲基二磷酸;氯化锶;比较研究

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中国基层医药

CiteScore

0.10

自引率

0.00%

发文量

32251

期刊介绍： Since its inception, the journal "Chinese Primary Medicine" has adhered to the development strategy of "based in China, serving the grassroots, and facing the world" as its publishing concept, reporting a large amount of the latest medical information at home and abroad, prospering the academic field of primary medicine, and is praised by readers as a medical encyclopedia that updates knowledge. It is a core journal in China's medical and health field, and its influence index (CI) ranks Q2 in China's academic journals in 2022. It was included in the American Chemical Abstracts in 2008, the World Health Organization Western Pacific Regional Medical Index (WPRIM) in 2009, and the Japan Science and Technology Agency Database (JST) and Scopus Database in 2018, and was included in the Wanfang Data-China Digital Journal Group and the China Academic Journal Comprehensive Evaluation Database.